

# M Eileen Dolan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7953262/publications.pdf>

Version: 2024-02-01

199  
papers

12,499  
citations

26630

56  
h-index

29157

104  
g-index

201  
all docs

201  
docs citations

201  
times ranked

18556  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular mechanisms of resistance and toxicity associated with platinating agents. <i>Cancer Treatment Reviews</i> , 2007, 33, 9-23.	7.7	1,338
2	Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS. <i>PLoS Genetics</i> , 2010, 6, e1000888.	3.5	1,161
3	Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase. <i>Progress in Molecular Biology and Translational Science</i> , 1995, 51, 167-223.	1.9	417
4	Testicular Cancer Survivorship: Research Strategies and Recommendations. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1114-1130.	6.3	260
5	Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics. <i>Journal of Clinical Oncology</i> , 2009, 27, 2604-2614.	1.6	236
6	Mouse models of human AML accurately predict chemotherapy response. <i>Genes and Development</i> , 2009, 23, 877-889.	5.9	235
7	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 815.	7.4	234
8	SCAN: SNP and copy number annotation. <i>Bioinformatics</i> , 2010, 26, 259-262.	4.1	214
9	Cancer Pharmacogenetics: Ethnic Differences in Susceptibility to the Effects of Chemotherapy. <i>Clinical Cancer Research</i> , 2009, 15, 4806-4814.	7.0	212
10	Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2712-2720.	1.6	197
11	Chemotherapy-induced peripheral neuropathy: Current status and progress. <i>Gynecologic Oncology</i> , 2016, 140, 176-183.	1.4	196
12	A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 9758-9763.	7.1	195
13	Evaluation of Genetic Variation Contributing to Differences in Gene Expression between Populations. <i>American Journal of Human Genetics</i> , 2008, 82, 631-640.	6.2	192
14	Cancer pharmacogenomics: strategies and challenges. <i>Nature Reviews Genetics</i> , 2013, 14, 23-34.	16.3	192
15	Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 1652-1661.	1.6	190
16	Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2277-2283.	1.6	178
17	Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1364-1368.	4.1	173
18	Identification of Genetic Variants Contributing to Cisplatin-Induced Cytotoxicity by Use of a Genomewide Approach. <i>American Journal of Human Genetics</i> , 2007, 81, 427-437.	6.2	173

#	ARTICLE	IF	CITATIONS
19	Genetic Architecture of Transcript-Level Variation in Humans. <i>American Journal of Human Genetics</i> , 2008, 82, 1101-1113.	6.2	142
20	Population differences in microRNA expression and biological implications. <i>RNA Biology</i> , 2011, 8, 692-701.	3.1	138
21	A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. <i>Cancer Research</i> , 2005, 65, 46-53.	0.9	133
22	Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N <sup>2</sup> -nitro-N-nitrosoguanidine. <i>Carcinogenesis</i> , 1984, 5, 1641-1647.	2.8	130
23	Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2000, 18, 3522-3528.	1.6	125
24	Genome-Wide Variation of Cytosine Modifications Between European and African Populations and the Implications for Complex Traits. <i>Genetics</i> , 2013, 194, 987-996.	2.9	117
25	Pharmacogenomic Discovery Using Cell-Based Models. <i>Pharmacological Reviews</i> , 2009, 61, 413-429.	16.0	109
26	Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity. <i>Cancer Research</i> , 2004, 64, 4353-4356.	0.9	108
27	Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 4486-4491.	6.4	103
28	Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9287-9292.	7.1	103
29	Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. <i>Pharmacogenomics</i> , 2012, 13, 55-70.	1.3	101
30	Chemotherapy-Induced Peripheral Neurotoxicity and Ototoxicity: New Paradigms for Translational Genomics. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju044-dju044.	6.3	94
31	Repair of O6-propylguanine and O6-butylguanine in DNA by O6-alkylguanine-DNA alkyltransferases from rat liver and <i>E. coli</i> . <i>Carcinogenesis</i> , 1985, 6, 1027-1031.	2.8	91
32	Modeling Chemotherapeutic Neurotoxicity with Human Induced Pluripotent Stem Cell-Derived Neuronal Cells. <i>PLoS ONE</i> , 2015, 10, e0118020.	2.5	88
33	Somatic Acquisition and Signaling of <i>TGFBR1</i> *6A in Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1634.	7.4	87
34	8-Substituted O6-Benzylguanine, Substituted 6(4)-(Benzoyloxy)pyrimidine, and Related Derivatives as Inactivators of Human O6-Alkylguanine-DNA Alkyltransferase. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 359-365.	6.4	86
35	Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 261-276.	7.7	84
36	Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 31-36.	4.1	82

#	ARTICLE	IF	CITATIONS
37	Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. <i>Blood</i> , 2009, 113, 2145-2153.	1.4	81
38	Modulation of Mammalian O6-Alkylguanine-DNA Alkyltransferase in vivo by O6-Benzylguanine and its Effect on the Sensitivity of a Human Glioma Tumor to l-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea. <i>European Journal of Implant and Refractive Surgery</i> , 1990, 2, 371-377.	0.3	81
39	Mapping Genes that Contribute to Daunorubicin-Induced Cytotoxicity. <i>Cancer Research</i> , 2007, 67, 5425-5433.	0.9	80
40	ExprTarget: An Integrative Approach to Predicting Human MicroRNA Targets. <i>PLoS ONE</i> , 2010, 5, e13534.	2.5	80
41	Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2232-2242.	4.1	77
42	Drug Focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. <i>Pharmacogenomics</i> , 2009, 10, 1897-1903.	1.3	77
43	Relating human genetic variation to variation in drug responses. <i>Trends in Genetics</i> , 2012, 28, 487-495.	6.7	76
44	Identification of common genetic variants that account for transcript isoform variation between human populations. <i>Human Genetics</i> , 2009, 125, 81-93.	3.8	75
45	Genetic Variants Contributing to Daunorubicin-Induced Cytotoxicity. <i>Cancer Research</i> , 2008, 68, 3161-3168.	0.9	74
46	Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. <i>Clinical Cancer Research</i> , 2019, 25, 1147-1155.	7.0	72
47	Substituted O6-Benzylguanine Derivatives and Their Inactivation of Human O6-Alkylguanine-DNA Alkyltransferase. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 342-347.	6.4	68
48	Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 547-555.	2.3	67
49	O6-benzylguanine-mediated enhancement of chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 943-8.	4.1	67
50	Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3038-3046.	4.1	66
51	Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. <i>Clinical Cancer Research</i> , 2017, 23, 3325-3333.	7.0	65
52	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5757-5768.	7.0	63
53	Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 471-476.	2.3	61
54	Regulatory Polymorphisms in $\beta$ -Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2012, 18, 4441-4448.	7.0	61

#	ARTICLE	IF	CITATIONS
55	Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2343-52.	7.1	59
56	Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. <i>Clinical Cancer Research</i> , 2002, 8, 2696-700.	7.0	59
57	Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. <i>RNA Biology</i> , 2009, 6, 412-425.	3.1	58
58	Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine. <i>Carcinogenesis</i> , 1991, 12, 2305-2309.	2.8	57
59	Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5490-5500.	7.0	57
60	Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. <i>Stem Cell Research</i> , 2017, 22, 79-88.	0.7	56
61	Identification and Validation of Genetic Variants that Influence Transcription Factor and Cell Signaling Protein Levels. <i>American Journal of Human Genetics</i> , 2014, 95, 194-208.	6.2	54
62	Variants Affecting Exon Skipping Contribute to Complex Traits. <i>PLoS Genetics</i> , 2012, 8, e1002998.	3.5	53
63	RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants. <i>Genome Biology</i> , 2019, 20, 254.	8.8	52
64	Creating and evaluating genetic tests predictive of drug response. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 568-574.	46.4	51
65	Identification of genomic regions contributing to etoposide-induced cytotoxicity. <i>Human Genetics</i> , 2009, 125, 173-180.	3.8	51
66	Genetics and Variable Drug Response. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 306-7.	7.4	50
67	Genetic Variants in Cytosolic 5'-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 9-23.	2.5	50
68	The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. <i>Bioinformatics and Biology Insights</i> , 2008, 2, BBI.S455.	2.0	49
69	Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. <i>Advanced Drug Delivery Reviews</i> , 1997, 26, 105-118.	13.7	48
70	Modulation of cyclophosphamide activity by O <sup>6</sup> -alkylguanine-DNA alkyltransferase. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 80-85.	2.3	47
71	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.	7.0	46
72	Allelic Loss at the GPx-1 Locus in Cancer of the Head and Neck. <i>Biological Trace Element Research</i> , 2004, 101, 097-106.	3.5	45

#	ARTICLE	IF	CITATIONS
73	Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. <i>Investigational New Drugs</i> , 2008, 26, 233-239.	2.6	45
74	Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 59-63.	2.3	43
75	Impact of the 1000 Genomes Project on the next wave of pharmacogenomic discovery. <i>Pharmacogenomics</i> , 2010, 11, 249-256.	1.3	43
76	Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. <i>Translational Research</i> , 2011, 157, 265-272.	5.0	42
77	Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. <i>Blood</i> , 2013, 121, 4366-4376.	1.4	42
78	Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 253-262.	1.5	41
79	Poly-Omic Prediction of Complex Traits: OmicKriging. <i>Genetic Epidemiology</i> , 2014, 38, 402-415.	1.3	41
80	Peripheral neuropathy in children and adolescents treated for cancer. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 744-754.	5.6	41
81	Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. <i>Anti-Cancer Drugs</i> , 1998, 9, 437-448.	1.4	40
82	Cell cycle arrest in a model of colistin nephrotoxicity. <i>Physiological Genomics</i> , 2013, 45, 877-888.	2.3	40
83	The Role of Gene Body Cytosine Modifications in <i>MGMT</i> Expression and Sensitivity to Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1334-1344.	4.1	40
84	Pharmacogenetics in Paclitaxel-Induced Sensory Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2015, 21, 4337-4346.	7.0	39
85	Enhancement of Cisplatin [ <i>cis</i> -Diammine Dichloroplatinum (II)] Cytotoxicity by <i>O</i> <sup>6</sup> -Benzylguanine Involves Endoplasmic Reticulum Stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 442-452.	2.5	38
86	Pharmacogenomics of chemotherapeutic susceptibility and toxicity. <i>Genome Medicine</i> , 2012, 4, 90.	8.2	38
87	Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. <i>Pharmacogenomics</i> , 2005, 6, 303-310.	1.3	36
88	Inhibition of Nuclear Factor- $\kappa$ B Activity by Temozolomide Involves <i>O</i> <sup>6</sup> -Methylguanine-Induced Inhibition of p65 DNA Binding. <i>Cancer Research</i> , 2007, 67, 6889-6898.	0.9	36
89	Linking the genetic architecture of cytosine modifications with human complex traits. <i>Human Molecular Genetics</i> , 2014, 23, 5893-5905.	2.9	36
90	A phase II trial of <i>O</i> 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 634-639.	2.3	35

#	ARTICLE	IF	CITATIONS
91	Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. <i>Carcinogenesis</i> , 2006, 28, 1111-1116.	2.8	35
92	Use of Cell Lines in the Investigation of Pharmacogenetic Loci. <i>Current Pharmaceutical Design</i> , 2009, 15, 3782-3795.	1.9	35
93	Population-specific GSTM1 copy number variation. <i>Human Molecular Genetics</i> , 2009, 18, 366-372.	2.9	34
94	Role of copper transporters in resistance to platinating agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 133-142.	2.3	34
95	SNPInProbe_1.0: A database for filtering out probes in the Affymetrix GeneChip® Human Exon 1.0 ST array potentially affected by SNPs. <i>Bioinformatics</i> , 2008, 2, 469-470.	0.5	33
96	Temozolomide: realizing the promise and potential. <i>Current Opinion in Oncology</i> , 2003, 15, 412-418.	2.4	32
97	Studies of the Repair of O 6 -Alkylguanine and O 4 -Alkylthymine in DNA by Alkyltransferases from Mammalian Cells and Bacteria. <i>Environmental Health Perspectives</i> , 1985, 62, 109.	6.0	31
98	Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 327-337.	1.5	30
99	Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. <i>Journal of the National Cancer Institute</i> , 2012, 105, 302-309.	6.3	30
100	The emerging role of microRNAs in drug responses. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 695-702.	2.8	30
101	Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 25, 103-108.	2.3	29
102	Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O 6 -Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins. <i>Clinical Cancer Research</i> , 2011, 17, 5748-5754.	7.0	29
103	Protein Quantitative Trait Loci Identify Novel Candidates Modulating Cellular Response to Chemotherapy. <i>PLoS Genetics</i> , 2014, 10, e1004192.	3.5	29
104	Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 498-507.	1.5	28
105	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e761-e769.	1.9	28
106	Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1127-35.	4.1	28
107	Effect of O 6 -benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327C model of prostatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 221-225.	2.3	27
108	Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 505-512.	2.3	27

#	ARTICLE	IF	CITATIONS
109	The Use of Genomic Information to Optimize Cancer Chemotherapy. <i>Seminars in Oncology</i> , 2011, 38, 186-195.	2.2	27
110	<i>RRM1</i> and <i>RRM2</i> pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. <i>Pharmacogenomics</i> , 2013, 14, 1449-1466.	1.3	27
111	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 4104-4116.	7.0	27
112	Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. <i>Pharmacogenomics</i> , 2007, 8, 1159-1168.	1.3	26
113	Mixed Effects Modeling of Proliferation Rates in Cell-Based Models: Consequence for Pharmacogenomics and Cancer. <i>PLoS Genetics</i> , 2012, 8, e1002525.	3.5	26
114	Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 207-220.	2.5	26
115	Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 633-40.	4.1	26
116	High Efficiency Electroporation of Human Umbilical Cord Blood CD34+Hematopoietic Precursor Cells. <i>Stem Cells</i> , 2001, 19, 492-499.	3.2	25
117	Copy number polymorphisms and anticancer pharmacogenomics. <i>Genome Biology</i> , 2011, 12, R46.	9.6	25
118	Using Germline Genomics to Individualize Pediatric Cancer Treatments. <i>Clinical Cancer Research</i> , 2012, 18, 2791-2800.	7.0	25
119	Identification of novel germline polymorphisms governing capecitabine sensitivity. <i>Cancer</i> , 2012, 118, 4063-4073.	4.1	25
120	Genome-Wide Local Ancestry Approach Identifies Genes and Variants Associated with Chemotherapeutic Susceptibility in African Americans. <i>PLoS ONE</i> , 2011, 6, e21920.	2.5	25
121	Clinical Translation of Cell-Based Pharmacogenomic Discovery. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 425-427.	4.7	24
122	Whole-genome approach implicates CD44 in cellular resistance to carboplatin. <i>Human Genomics</i> , 2009, 3, 128.	2.9	23
123	Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 206-213.	2.5	21
124	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2011, 38, 215-224.	2.2	21
125	Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 831-838.	2.3	21
126	Hydroxylation and N-Dechloroethylation of Ifosfamide and Deuterated Ifosfamide by the Human Cytochrome P450s and Their Commonly Occurring Polymorphisms. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1084-1090.	3.3	21



#	ARTICLE	IF	CITATIONS
127	Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair, 2007, 6, 1145-1154.	2.8	20
128	The effects of O <sup>6</sup> -benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemotherapy and Pharmacology, 1993, 32, 477-481.	2.3	19
129	Anti-neoplastic activity of sequenced administration of O <sup>6</sup> -benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochemical Pharmacology, 1994, 48, 2127-2134.	4.4	19
130	Intraarterial O <sup>6</sup> -benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology, 1997, 39, 307-316.	2.3	19
131	Population Differences in the Rate of Proliferation of International HapMap Cell Lines. American Journal of Human Genetics, 2010, 87, 829-833.	6.2	19
132	SCAN database: facilitating integrative analyses of cytosine modification and expression QTL. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav025-bav025.	3.0	19
133	O <sup>6</sup> -Benzylguanine-mediated enhancement of nitrosourea activity in Mer <sup>+</sup> central nervous system tumor xenografts - implications for clinical trials. Cancer Chemotherapy and Pharmacology, 2000, 45, 437-440.	2.3	18
134	Comprehensive Survey of SNPs in the Affymetrix Exon Array Using the 1000 Genomes Dataset. PLoS ONE, 2010, 5, e9366.	2.5	18
135	Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Human Molecular Genetics, 2013, 22, 4007-4020.	2.9	18
136	Evaluation of inter-batch differences in stem-cell derived neurons. Stem Cell Research, 2016, 16, 140-148.	0.7	17
137	Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O <sup>6</sup> -benzylguanine. Cancer Chemotherapy and Pharmacology, 2005, 55, 333-342.	2.3	16
138	Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects. Current Bioinformatics, 2008, 3, 178-182.	1.5	16
139	An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Human Molecular Genetics, 2012, 21, 1470-1480.	2.9	16
140	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 5913-5924.	7.0	16
141	EPS8 Inhibition Increases Cisplatin Sensitivity in Lung Cancer Cells. PLoS ONE, 2013, 8, e82220.	2.5	16
142	Determination of the optimal modulatory dose of O <sup>6</sup> -benzylguanine in patients with surgically resectable tumors. Clinical Cancer Research, 2002, 8, 2519-23.	7.0	16
143	Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biology, 2009, 9, 55-63.	0.9	15
144	Debenzylation of O <sup>6</sup> -benzyl-8-oxoguanine in human liver: implications for O <sup>6</sup> -benzylguanine metabolism. Biochemical Pharmacology, 2001, 61, 721-726.	4.4	14

#	ARTICLE	IF	CITATIONS
145	Pharmacogenomics of <scp>cisplatinâ€induced</scp> neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. <i>Cancer Medicine</i> , 2022, 11, 2801-2816.	2.8	14
146	The role of O6-alkylguanine-DNA alkyltransferase in protecting Rat4 cells against the mutagenic effects of O6-substituted guanine residues incorporated in codon 12 of the H-ras gene. <i>Carcinogenesis</i> , 1993, 14, 593-598.	2.8	13
147	Approaches to the discovery of pharmacogenomic markers in oncology: 2000â€2010â€2020. <i>Pharmacogenomics</i> , 2010, 11, 471-474.	1.3	13
148	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 459-468.	4.9	13
149	Role of GADD34 in modulation of cisplatin cytotoxicity. <i>Biochemical Pharmacology</i> , 2006, 71, 239-247.	4.4	12
150	Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. <i>Scientific Reports</i> , 2018, 8, 733.	3.3	12
151	Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 775-786.	3.8	12
152	Identification of small molecules that mitigate vincristineâ€induced neurotoxicity while sensitizing leukemia cells to vincristine. <i>Clinical and Translational Science</i> , 2021, 14, 1490-1504.	3.1	12
153	Modified Guanines Representing O6-Alkylation by the Cyclophosphamide Metabolites Acrolein and Chloroacetaldehyde: A Synthesis, Stability, and ab Initio Studies. <i>Chemical Research in Toxicology</i> , 2002, 15, 380-387.	3.3	11
154	Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. <i>Clinical Cancer Research</i> , 2017, 23, 4010-4019.	7.0	11
155	On the challenges of the HapMap resource. <i>Bioinformatics</i> , 2008, 2, 238-239.	0.5	11
156	An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level. <i>Journal of Medicinal Chemistry</i> , 1983, 26, 1656-1659.	6.4	10
157	Inactivation of O 6-alkylguanine-DNA alkyltransferase by 8-substituted O 6-benzylguanine analogs in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 63-69.	2.3	10
158	Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1247-1255.	2.5	10
159	Identification of genetic variants associated with capecitabine-induced handâ€foot syndrome through integration of patient and cell line genomic analyses. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 231-237.	1.5	10
160	Sequential therapy with dacarbazine and carmustine: a phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 509-514.	2.3	9
161	The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. <i>Biochemical Pharmacology</i> , 2009, 77, 1586-1592.	4.4	9
162	Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. <i>Pharmacogenomics</i> , 2013, 14, 1383-1387.	1.3	9

#	ARTICLE	IF	CITATIONS
163	Characterization of CpG sites that escape methylation on the inactive human X-chromosome. <i>Epigenetics</i> , 2015, 10, 810-818.	2.7	9
164	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. <i>Clinical Cancer Research</i> , 2020, 26, 6550-6558.	7.0	9
165	Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?. <i>Pharmacogenomics</i> , 2013, 14, 447-450.	1.3	8
166	Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations. <i>Human Molecular Genetics</i> , 2021, 30, 305-317.	2.9	8
167	Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 291-302.	2.3	7
168	O6-Methylguanine-DNA Methyltransferase Activity and Promoter Methylation Status in Pediatric Rhabdomyosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 941-947.	0.6	7
169	Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. <i>Human Molecular Genetics</i> , 2012, 21, 4348-4355.	2.9	7
170	Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 644-652.	4.7	7
171	Silence Is Golden: Gene Hypermethylation and Survival in Large-Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 6-7.	6.3	6
172	Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 623-633.	2.5	6
173	Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. <i>Cancer</i> , 2021, 127, 4091-4102.	4.1	6
174	Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. <i>Trends in Cancer Research</i> , 2008, 4, 1-13.	1.6	6
175	Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 569-573.	2.3	5
176	Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure. <i>Mutagenesis</i> , 2008, 23, 341-346.	2.6	5
177	Comprehensive Evaluation of the Contribution of X Chromosome Genes to Platinum Sensitivity. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 472-480.	4.1	5
178	Metabolism and Disposition of O6-Benzyl-2'-deoxyguanosine in Sprague-Dawley Rats. <i>Chemical Research in Toxicology</i> , 1994, 7, 762-769.	3.3	4
179	1,3- vs 1,5-Intramolecular Alkylation Reactions in Isophosphoramidate and Phosphoramidate Mustards. <i>Chemical Research in Toxicology</i> , 2004, 17, 1217-1226.	3.3	4
180	The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 881-887.	2.3	4

#	ARTICLE	IF	CITATIONS
181	Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy. <i>Journal of Proteome Research</i> , 2017, 16, 4227-4236.	3.7	3
182	Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2020, 26, 2891-2897.	7.0	3
183	Intracellular activation of cytotoxic agents: kinetic models for methyl nitrosoureas and N-methyl-N'-nitro-N-nitrosoguanidine in cell culture. <i>Chemical Research in Toxicology</i> , 1989, 2, 157-161.	3.3	2
184	Pharmacokinetics of oral O 6 -benzylguanine and evidence of interaction with oral ketoconazole in the rat. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 150-155.	2.3	2
185	Pharmacogenomics " Racing Towards Personalized Prescriptions. <i>Laboratory Medicine</i> , 2003, 34, 651-659.	1.2	2
186	Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. <i>International Journal of Molecular Sciences</i> , 2017, 18, 661.	4.1	2
187	HapMap filter 1.0: A tool to preprocess the HapMap genotypic data for association studies. <i>Bioinformatics</i> , 2008, 2, 322-324.	0.5	2
188	Systems and genome-wide approaches unite to provide a route to personalized medicine. <i>Genome Medicine</i> , 2012, 4, 29.	8.2	1
189	Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5016-5016.	1.6	1
190	Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12063-12063.	1.6	1
191	Adapting Pathway Programs to the Virtual World: Insights from the Chicago EYES on Cancer Response to COVID-19-Related Disruptions to Training. <i>Journal of STEM Outreach</i> , 2021, 4, .	0.5	1
192	Sequential therapy with dacarbazine and carmustine: a phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 509-514.	2.3	1
193	Oncologic Drugs. , 0, , 97-114.		0
194	Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. <i>Pharmacogenomics Journal</i> , 2019, 19, 178-190.	2.0	0
195	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12004-12004.	1.6	0
196	Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy-Related Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 1829-1829.	1.4	0
197	Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response. , 2008, , 19-31.		0
198	Identification of pharmacogenetic target genes associated with chemotherapy-induced peripheral neuropathy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13541-e13541.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Influence of polymorphisms discovered in cell-based model of cytarabine sensitivity on outcome in pediatric AML: A Children's Oncology Group Study.. Journal of Clinical Oncology, 2014, 32, 10040-10040.	1.6	0